{"name":"Xencor, Inc.","slug":"xencor-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":125576000,"revenueGrowth":13.7,"grossMargin":0,"rdSpend":239434000,"netIncome":-91923000,"cash":875495000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQbldvUXJacU0tNnhOM0tMZFpxeFdpTUhhcWFPbzYwWVNOaVdOR0swcVV4MDNpdjlpNHZzUllWNHdvT1FobUNxeXVvb3lFVzNGUXVJTmg5WEljNkdJaVF2ZE5zemRfenhwN3NGZHgwbV9mb0cwenM3X05YVmsxMy1XN29LNU1iWjhLcXJUNjBkdzRLVXJfYVRiRkN1ckxRY1VDUHRyaTVOUnFwRVF1WnVuUUswOUZnYmwzR1RhYnVhb1M4TE9XV0I2Tk5nRnRVX1dhaW1PeW03Z2RlMUNucUJlZzNMd0xJVzY4S1FnVnh2WDBjbVJwWlpLSUZSTXV0azRZeFhwdE5OdUg3dw?oc=5","date":"2026-03-28","type":"regulatory","source":"The Globe and Mail","summary":"Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail","headline":"Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9lX2NNQURQbE1jSnZkVFlEZFcycFV5M0R6WVltQTZ6ZHZsZmN4MGMtN0drSHNHdXRiclpCMEwzZDgzWVdUMC1UQ3ZwYUU4SFplU040b1pib2MwVXc?oc=5","date":"2026-03-21","type":"earnings","source":"Intellectia AI","summary":"XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI","headline":"XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNcHJMWkcxakp4RWlyR0hlczhNRzg3RzBGVlRmdFdvd2VZc3NNS0UzNGhJak1iWDV1TTNhekxNWC03VC1QSzVGMm1wZFNScWtVUlJidnUwaUc2dFdXZEptMDZJWWloX3NlTkVEQ3Q0LW9kMGJTdFhsNWtzS2tVTGVaTFJPZkpBUQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Seeking Alpha","summary":"Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha","headline":"Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZ29Kc3Fya3VnSEtkekpqQ1BiS214RUVkS1RZNzZWSll0eEtYQVJQSmF5T0F1Y01QSWYzOGxxaWpJQWF3YWZnMW1jRkJWTGtvaHZieUVYenAta0NVTHVONFdGdG81ODhmako0YUUzSk1vMmtsOVFrUXhfRXdoYThaOG8zWFhGa0praGd6elRFRkg3dF9Hd2VLd3Bocm5xX0VhSG92Z29RWW5DeUk?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Xencor faces $100M hit as Ultomiris US royalty checks stop - Stock Titan","headline":"Xencor faces $100M hit as Ultomiris US royalty checks stop","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNSDZMZEEtZG5SMXN2bHV1WnlULVdKV3pabTdsSUhXeWo2a2wyMTRFT1M2OFFJQ2RXWHJMRHo5TmZIT1lxakx6d3FMZTVUMXJVNlh0NkdLZFRWZVZFSzM4UmJQWkd6cUs2Z1VOZllKQ19xZFRlWXZ4RnZ0REoza2YwekpIOWdKOV9DZDhic2tCWm85WndSOEdvTllvSlVoY3h5VlEwMy1uak5QVmtLaDNadA?oc=5","date":"2026-02-23","type":"pipeline","source":"Business Wire","summary":"Xencor to Participate at Upcoming Investor Conferences - Business Wire","headline":"Xencor to Participate at Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"pipeline","source":"simplywall.st","summary":"Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate - simplywall.st","headline":"Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOZWw1b1Y0X0VOSDItT093T3h3ODNSN1hVMmRJYk1GX2kxZjFhZVg3ajhuUVh1QVZFd3k2a1pJMzVtbnYtZFFmWTFKRWJPclZwYTRZNWYwUU9JTXQwbHJ4aVItdXNUUVJzM04tUlQwTGxZd182cHBXbzBvWVBab3pKNk45WUQ4QQ?oc=5","date":"2026-01-12","type":"pipeline","source":"labusinessjournal.com","summary":"ImmunityBio, Xencor Drugs Win E.U. Nods - labusinessjournal.com","headline":"ImmunityBio, Xencor Drugs Win E.U. Nods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQbHNGdHg5QWNheHRlaXlXNWl4MzE2cndjbnBPSE50RUQ3Z1l6dW9GdnpScHdqRWt6QTZCLUlIUl92OEE5MXd3N0ZlRWdZaUpNOE9QdjVGZzJxNXhGZjc0b1V6VmdhVW8yT0U4cW9WT2o5d2t4RkRsdXdyR0JEVWJjd1dvdUdQT0hJcVhJbVBiMVBteUZhNkFVZnNPWm8yUmk2a2hFeDVLUzZyMzQ5MVBrNE9PLXM2MWZtMUZMaFY1c3lTbEstcjlVckpmcTJidWI3UU5pNTlweUw1TGZ6dFJONU5CQk8tVWhKTDZJUV9CaTdsMS03LWdSLUJiSU94T3piYk9MbmFPNi1YZDg?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOVJWQjJvYWhZdmJSOFllcjVyeHBCU0hQTlZCWDVXNnhfdmJ6VXVaR2R4U1NrRnVVRVAwRTIwd21SV1NHckhkRktFUERvdVp6VWxuRnhId0lsakp1cHB5ZVczMnZyNm9hbUFRS3dKYWhtd3RNRDIyZ09kWUVWeGhGQUlsTE1Lekhxd0lET2dPM2lnVFpVbWR2dS00TGU5R05iNkxFMng0dmJEM1ZpM3dCQUcyRmozd3NzcUN4Mi1jRGh5QQ?oc=5","date":"2026-01-08","type":"pipeline","source":"Business Wire","summary":"Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire","headline":"Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQOC1wcF8xRy1qTVA1UWU2bjhTLUNOUmJvYXNFRTB2YXNfYmtQemx4TnExcEExUTB0ZHh3clBGM1MwUl94TFRSWkFCUTlYS1M5NUxfYndHTnZCMVFhUEFBVFFra1ZRTi1uNDFpS3dmSVV1anl0S1ptc0RtVTFpRTFpZkVVZDE5SzRm?oc=5","date":"2025-12-09","type":"patent","source":"Yahoo Finance","summary":"Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Yahoo Finance","headline":"Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNRlhGcmV5eGFlcFBUTTUzdXVSeGhwMDA1MEhXc0JaSlVLSXk1blVlcXRTUEFkM0hwbHJTSzNkTU14TkZpczMzUGZQU2FQNDRJOGFFeGlSOUV0SXNmQVEzR2lSd2o0QVV5S21ob1lqdUVIWkNWZ1FMX1B1bDJrT0dobkdOaW5DQ2YwSUF6MkIwSlljbkRCQ3Btd3ZILTExaGhRczNuYlA2WQ?oc=5","date":"2024-11-04","type":"pipeline","source":"IPWatchdog.com","summary":"Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com","headline":"Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOYmxGSFNiaERfNlQzdnBKcVpINzV4bWs1N2tJR3BfbTZxVkpJMG5YMXl2YlN4X0lRei1tWTNNWmhTeS1xdVNUMFRWb09NaUR2XzU3UVJBZEtUaVNYbGFhU0NiWE5WcVhtelNxZXBjeFhOM1p0d1Q0djg0ci1FcDdqdmlqQUZiU3BMTmtsb3VFQUFkTUFVNVRDYTNwS3NjOUxrN0NWUnVoR0tfSUlwRmRj?oc=5","date":"2021-11-09","type":"deal","source":"BioSpace","summary":"Novartis Walks Away from $2.6 Billion Xencor Collaboration - BioSpace","headline":"Novartis Walks Away from $2.6 Billion Xencor Collaboration","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":125576000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":125576000,"period":"2025-12-31"},{"value":110493000,"period":"2024-12-31"},{"value":110493000,"period":"2024-12-31"},{"value":168338000,"period":"2023-12-31"},{"value":174615000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":239434000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-91923000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":875495000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}